Filgotinib: First Approval
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical)
Link
http://link.springer.com/content/pdf/10.1007/s40265-020-01439-0.pdf
Reference46 articles.
1. Banerjee S, Biehl A, Gadina M, et al. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017;77(5):521–46.
2. O’Shea JJ, Schwartz DM, Villarino AV, et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311–28.
3. European Medicines Agency. Filgotinib (Jyseleca®): summary of product characteristics. 2020. https://www.ema.europa.eu/. Accessed 30 Sep 2020.
4. Durez P, Hoekema A, Huizinga T, et al. Treatment innovation for patients: a collaborative network in the Benelux and an inside view of 20 years of Galapagos. Acta Clin Belg. 2020. https://doi.org/10.1080/17843286.2020.1812830.
5. Gilead Sciences. Jyseleca® (filgotinib) approved in Japan for rheumatoid arthritis [media release]. 25 Sep 2020. https://www.gilead.com.
Cited by 53 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Safety and Effectiveness of Thiopurines and Small Molecules in Elderly Patients with Inflammatory Bowel Diseases;Journal of Clinical Medicine;2024-08-09
2. Pharmacokinetic review of janus kinase inhibitors and its clinical implications for the management of rheumatoid arthritis;Expert Opinion on Drug Metabolism & Toxicology;2024-06-26
3. Janus Kinases and Autoimmunity: Bridging Pathways to Therapy;International Journal of Drug Discovery and Pharmacology;2024-06-05
4. Small molecule drug discovery targeting the JAK-STAT pathway;Pharmacological Research;2024-06
5. FDA-Approved Janus Kinase-Signal Transducer and Activator of Transcription (JAK-STAT) Inhibitors for Managing Rheumatoid Arthritis: A Narrative Review of the Literature;Cureus;2024-05-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3